Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KB113
- Development stage
- Unknown
- Lead developer
- Krystal Biotech
- Modality
- Gene Therapies
- Administration
- Intratumoral
01
Overview
KB113 is an investigational, replication-defective herpes simplex virus type 1 (HSV-1)-based gene therapy designed to deliver genes encoding human interleukin-2 (IL-2) and interleukin-12 (IL-12) directly to the tumor microenvironment. Developed by Krystal Biotech, KB113 is a low-dose formulation of intratumoral KB707. It is designed to drive sustained, localized expression of IL-2 and IL-12, promoting systemic immune-mediated tumor clearance and inducing an abscopal effect. KB113 is being evaluated for the treatment of basal cell carcinomas (BCCs) in patients with Gorlin syndrome, a rare genetic disorder characterized by a high risk of developing multiple BCCs.
Beyond the preview
Go deeper on KB113.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KB113.